Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23995192 | 0.78 | CYP17A1 (0.38) | CYP17A1CYP1A2PLK4 | |
| SCHEMBL30224680 | 0.78 | CYP17A1 (0.38) | CYP17A1CYP1A2PLK4 | |
| SCHEMBL30224584 | 0.72 | NT5E (0.35) | — | |
| SCHEMBL30182171 | 0.70 | KDM4E (0.46) | CYP17A1CYP1A2 | |
| SCHEMBL23994571 | 0.69 | KCNJ6 (0.39) | CYP17A1CYP1A2 | |
| SCHEMBL29259782 | 0.68 | — | — | |
| SCHEMBL16084393 | 0.68 | CDK9 (0.42) | CYP1A2 | |
| SCHEMBL30224821 | 0.67 | HTR2A (0.31) | CYP17A1CYP1A2 | |
| SCHEMBL25004868 | 0.66 | PDE10A (0.33) | CYP17A1CYP1A2 | |
| SCHEMBL23994190 | 0.66 | KMO (0.55) | CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270174-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4422756-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279186-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11919869-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230183189-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183189-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183189-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023077030-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270174-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885PLK4 3908/4885 |
| US-11919869-B2 | CD73 compounds | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885PLK4 3908/4885 |
| US-20230183189-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885PLK4 3908/4885 |
| US-20240279186-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | CYP17A1 1658/4885CYP1A2 1087/4885PLK4 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.